



EP PerMed
European Partnership
for Personalised Medicine

EUROPEAN PARTNERSHIP

Joint Transnational Call for Proposals (2027) for

Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)

(EP PerMed Grant 101137129)

Pre-announcement

For further information, please visit our website: www.eppermed.eu
or contact EPPerMed@anr.fr



**Co-funded by
the European Union**

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

Preliminary Announcement for the Joint Transnational Call (JTC) 2027

The **European Partnership for Personalised Medicine, EP PerMed** (supported by the European Union under Horizon Europe, Grant Agreement N° 101137129), is a platform for joint programming of national and European regional research and innovation supporting activities putting into action “The Strategic Research & Innovation Agenda (SRIA) for Personalised Medicine (2023)”¹, **SRIA for PM (2023)**, through dedicated research, development and innovation funding.

The EP PerMed funding organisations listed below have agreed to launch the joint transnational call 2027 (JTC2027) “Cell and Gene Therapy for Personalised Medicine” (acronym: CGT4PM2027), co-funded by the European Union, to fund multinational, innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe and beyond in this field. The JTC2027 will be conducted simultaneously by the participating funding organisations in their respective region/country and coordinated centrally by the Joint Call Secretariat (JCS), hosted by the French National Research Agency (ANR), France.

The call will be implemented in two stages, i.e. a pre- and a full proposal phase. The available budget for this call is **33 Mio. € (approx.)**.

Expected timeline of the call

04 November, 2026	Publication of the call
03 December, 2026	Information day
20 January, 2027 (14:00, CET)	Deadline for pre-proposal submission
Beginning of April, 2027	Communication of the results of the pre-proposal assessment and invitation to the full proposal stage
25 May, 2027 (14:00, CEST)	Deadline for full proposal submission
Beginning of August 2027	Rebuttal stage
Expected for October 2027	Communication of the funding decisions to the applicants
End of 2027, beginning of 2028	Expected project start (according to regional/national funding regulations)

¹ <https://www.eppermed.eu/action-areas/sria/>

Aims of the Call

With this JTC, EP PerMed will fund research projects in human health on Cell and Gene Therapy (CGT) for PM approaches. Proposals must focus on the development and validation of an innovative and novel CGT for PM.

At least one of the following approaches must be employed:

- Somatic cell therapeutics;
- Gene therapeutics;
- Combined cell- and gene therapeutics;
- Novel biological products such as mRNA, other nucleic acid-based methods, and extracellular vesicles as vehicle for gene-based therapeutic procedure.

Research projects in all disease areas are encouraged.

The EP PerMed overall aims to:

- Encourage and enable interdisciplinary collaborations, i.e. multi-actor research, by engaging a range of relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to facilitate the implementation of PM;
- Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises, industry), as well as regulatory/HTA (health technology assessment) agencies and patient organisations.

General (Eligibility) Conditions for Application

Joint research proposals may be submitted by applicants belonging to the following categories (subject to regional/national funding regulations):

- A. Academia** (research teams working in universities, other higher education institutions) **or research institutes;**
- B. Clinical/public health sector** (research teams working in hospitals/public health and/or other healthcare settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses) in the research teams is encouraged;
- C. Private for-profit (industry) partners, e.g. SME** (small and medium-sized enterprises) and **private non-profit partners, e.g. foundations, associations or non-governmental organisations.**

Whilst applications will be submitted jointly by groups from several countries, the individual applicants of each group will be funded by the respective regional/national EP PerMed funding organisation of the individual applicants. The applications are therefore subject to eligibility criteria and regulations of individual funding organisations. Applicants are strongly advised to contact their regional/ national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also below “*Contact details of participating members*”).

More information about the eligibility criteria and rules regarding consortium composition will be available soon.

Partnering Tool

A partnering tool developed and supported by the EP PerMed is available for the call: <https://www.b2match.com/e/eppermed-partnering> .

Participating Countries and European Regions

The following countries (25) are participating in the preparation of the call: Austria, Belgium*, Canada, Czech Republic, Estonia, Finland, France*, Germany, Greece*, Hungary, Ireland, Israel, Italy*, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal*, Romania, Slovak Republic, Spain, Sweden, The Netherlands* and Turkiye* (contact list is provided below).

Five of the participating countries are represented by their specific regions (10): Flanders (Belgium)*, Wallonia-Brussels Federation (Belgium), Wallonia (Belgium), Saxony (Germany), Friuli-Venezia Giulia (Italy), Lombardy (Italy)*, Tuscany (Italy), Azores (Portugal), Andalusia (Spain), and Catalonia (Spain).

** Decision on participation is still pending.*

Cooperation with Xjenza Malta

For the JTC2027, EP PerMed is cooperating with the [Maltese funding agency Xjenza Malta](#). Through the Access2Partnerships (A2P) Scheme, Malta-based researchers participating in the EP PerMed Call as partners on own funds may be eligible for up to €300,000 per project to support their involvement in a successfully selected proposal, subject to a successful national application to Xjenza Malta.

Further information on the national application procedure, specific scheme deadlines, eligibility requirements, applicable conditions and submission requirements can be found on Xjenza Malta's [Access2Partnerships \(A2P\) Scheme webpage](#).

Cooperation with Breakthrough T1D

In the framework of the Joint Transnational Call (JTC) 2027 “Cell and Gene Therapy for Personalised Medicine” (CGT4PM2027), **Breakthrough T1D** offers the opportunity for researchers based anywhere in the world to participate as self-funded partners in successfully selected proposals with a clear focus on Type 1 Diabetes (T1D).

Researchers interested in receiving funding from Breakthrough T1D are required to contact Breakthrough T1D at least 15 working days before the JTC pre-proposal deadline (email to churtadodelpozo@breakthrough1d.org) to discuss scientific alignment and procedural requirements. Any potential involvement or support from Breakthrough T1D is subject to a separate internal review and approval process and is not automatically guaranteed through participation in the JTC.

Please note:

The information provided in this pre-announcement is indicative and may be subject to changes and is not legally binding to funding organisations. Additional funding organisations might join the call before the official publication or leave the funders consortium.

Interested applicants are encouraged to initiate scientific contacts with potential project consortium partners for applications.

The final call information is expected to be published on the EP PerMed website in November 2026.

For more information: <https://www.eppermed.eu/jtc2027/>

List of Regional/National Contacts

<i>Name of participating organisation</i>	<i>Country/ Region</i>	<i>Regional/National contact</i>
Austrian Science Fund, (FWF)	Austria	Hannes Zwickl hannes.zwickl@fwf.ac.at Tel.: +43 676 83487 8219 Heike Höller heike.hoeller@fwf.ac.at Tel.: +43 676 83487 8220
The Research Foundation – Flanders, (FWO)*	Belgium (Flanders)	Kristien Peeters (SBO) Tel.: +32 (0)2 550 15 95 Toon Monbaliu (FO) Tel.: +32 (0)2 550 15 70 europe@fwo.be
Vlaams Gewest - VLAIO Flanders Innovation & Entrepreneurship, (FIO/VLAIO)	Belgium (Flanders)	Ariane Tiberghien Ariane.Tiberghien@vlaio.be Tel: +32479291349
Fund for Scientific Research – FNRS, (F.R.S.-FNRS)	Belgium (Wallonia-Brussels Federation)	Maxime Bonsir maxime.bonsir@frs-fnrs.be Tel.: +32 2 504 92 36 Joël Groeneveld Tel.: +32 2 504 92 70 international@frs-fnrs.be
Service Public de Wallonie (SPW EER)	Belgium (Wallonia)	Vinciane Grimard vinciane.grimard@spw.wallonie.be Tel: +32 (0)81 77 87 18
Canadian Institutes of Health Research (CIHR)	Canada	Pierre-Luc Coulombe PDD-IGStrategic-CEP-IGStrategique@cihr-irsc.gc.ca
The Ministry of Health of the Czech Republic (MZCR)	Czech Republic	Monika Kocmanova Monika.kocmanova@azvcr.cz Tel.: +420 778 973 186 Olga Laaksonen Olga.laaksonen@mzd.gov.cz Tel.: +420 604 786 141
Estonia Enterprise (EIS)	Estonia	Alice Liblik alice.liblik@eis.ee Tel : +372)6279738 Reet Reinart-Okugbeni reet.reinart@eis.ee Tel : (+372)56980087
Estonian Research Council, (ETAG)	Estonia	Margit Suuroja Margit.Suuroja@etag.ee Tel.: +372 731 7360 Argo Soon Argo.Soon@etag.ee Tel.: +372 515 3424

<i>Name of participating organisation</i>	<i>Country/ Region</i>	<i>Regional/National contact</i>
Business Finland, (BFRK)	Finland	Norma Saha norma.saha@businessfinland.fi Tel.: +358 50 5577 012 Matti Hiltunen matti.hiltunen@businessfinland.fi Tel.: +350 50 5577652
Agence Nationale de la Recherche, (ANR)*	France	Mylène Vaillancourt Tel.: (+33) (0) 1 78 09 80 36 Mérck Machouri Tel.: (+33) (0) 1 72 73 06 72 EPPerMed@agencerecherche.fr
Federal Ministry of Research, Technology and Space, (BMFTR) German Aerospace Center e.V. – Project Management Agency, (DLR)	Germany	Ute Preuss Alexandra Becker Permed@dlr.de Tel.: +49 (0) 228 3821 2211
Federal Ministry of Health, (BMG) German Aerospace Center e.V. – Project Management Agency, (DLR)	Germany	Fabian Gondorf Joachim Burbiel PerMed@dlr.de Tel.: +49 (0) 228 3821 2211
Saxon State Ministry for Science, Culture and Tourism, (SMWK)	Germany (Saxony)	Gabriele Süptitz gabriele.sueptitz@smwk.sachsen.de Tel.: +49 351 564-64210 Caroline Karapanos caroline.karapanos@smwk.sachsen.de Tel.: +49 351 564-64220
General Secretariat for Research & Innovation, (GSRI)*	Greece	Foteini Karagkouni f.karagkouni@gsri.gov.gr Tel.: +30 213 1300062
National Research, Development and Innovation Office, (NKFIH)	Hungary	Zsuzsanna Kürti ncp@nkfi.gov.hu
Taighde Éireann-Research Ireland, (TE-RI)	Ireland	Suzan Gunbay suzan.gunbay@researchireland.ie
Chief Scientist Office, Ministry of Health, (CSO-MOH)	Israel	Liron Even-Faitelson Liron.ef@moh.gov.il Tel.: +972-2-5082168
National Technological Innovation Authority, (IIA)	Israel	Sarah Chiche sarah.c@innovationisrael.org.il Tel.: +972 3 5118122
Italian Ministry of Health, (IT-MoH)	Italy	Simona Carmen Ursu sc.ursu@sanita.it Alessandra Vittoria Lallo av.lallo@sanita.it

<i>Name of participating organisation</i>	<i>Country/ Region</i>	<i>Regional/National contact</i>
Regione Autonoma Friuli Venezia Giulia	Italy (Friuli-Venezia Giulia)	Ketty Segatti ketty.segatti@regione.fvg.it Tel: +39 040 3775206 Luciana Grimaldi Luciana.grimaldi@regione.fvg.it Tél: +39 040 3775274
Fondazione Regionale per la Ricerca Biomedica, (FRRB)*	Italy (Lombardy)	Giulia Maria Rossignolo giuliamaria.rossignolo@frrb.it bandi@frrb.it Tel.: +39 0267650159
Tuscany Region, (RT)	Italy (Tuscany)	Teresa Vieri Tel.: +39 055 4383289 Monica Malacarne Tel: +39 0554382334 eppermed@regione.toscana.it
Latvian Council of Science, (LZP)	Latvia	Uldis Berkis Uldis.Berkis@lzp.gov.lv Tel.: +371-29472349
Research Council of Lithuania, (LMT)	Lithuania	Živilė Ruželė zivile.ruzele@lmt.lt Tel.: (+370) 676 14383
National Research Fund, (FNR)	Luxembourg	Gideon Gießelmann gideon.giesselmann@fnr.lu Tel.: +352 691 362 805
The Research Council of Norway, (RCN)	Norway	Karianne Solaas, kso@rcn.no Tel.: +47 945 35 380
National Centre for Research and Development, (NCBR)	Poland	Anna Stępień anna.stepien@ncbr.gov.pl Tel.: +48 22 39 07 210
Fundação para a Ciência e a Tecnologia, (FCT)*	Portugal	Rita Cavaleiro Tel.: +351 213 911 541 Pedro Ferreira Tel.: +351 213 924 445 EPPerMed@fct.pt
Vice-Presidency of Azores Regional Government, (VP-GRA)	Portugal (Azores)	Sara de Viveiros Pavão sara.v.pavao@azores.gov.pt Tel.: +351 296 308 903
Executive Agency for Higher Education, Research, Development and Innovation Funding, (UEFISCDI)	Romania	Mihaela Manole mihaela.manole@uefiscdi.ro Nicoleta Dumitrache nicoleta.dumitrache@uefiscdi.ro

<i>Name of participating organisation</i>	<i>Country/ Region</i>	<i>Regional/National contact</i>
Centrum vedecko-technických informácií Slovenskej republiky, (CVTI SR)	Slovak Republic	Maros Halama maros.halama@cvtisr.sk Tel: +421 917 733 475
National Institute of Health Carlos III, (ISCIII)	Spain	Cándida Sánchez Barco eppermed@isciii.es
Consejería de Presidencia, Sanidad y Emergencias de la Junta de Andalucía , (CPSEJA)	Spain (Andalusia)	Alicia Milano Curto ep.fps@juntadeandalucia.es
Health Department – Generalitat de Catalunya, (DS-CAT)	Spain (Catalonia)	Carme Pérez peris@gencat.cat Tel.: +34 935566103
Swedish Research Council, (SRC)	Sweden	Abraham Mellkvist-Roos abmr@vr.se Tel.: +46 76 525 7613
Sweden's Innovation Agency, (VINNOVA)	Sweden	Casper Ullsten-Wahlund casper.ullsten-wahlund@vinnova.se Tel.: +46 8 473 32 06
The Netherlands Organisation for Health Research and Development, (ZonMw)*	The Netherlands	Rob Diemel Marcella de Boer Anna Wilbers EP-PerMed@zonmw.nl Tel.: +31 70 349 5252
The Scientific and Technological Research Council of Türkiye, (TUBITAK)*	Türkiye	N. Selcan TÜRKER selcan.turker@tubitak.gov.tr Tel.: +90 312 298 1760

* Final decision for participation is still pending.